CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares of the company's stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Samarth Kulkarni also recently made the following trade(s):
- On Friday, March 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $72.48, for a total transaction of $1,449,600.00.
- On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $78.26, for a total transaction of $767,104.52.
- On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90.
- On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00.
- On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00.
CRISPR Therapeutics Stock Performance
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
NASDAQ CRSP opened at $55.56 on Thursday. The firm has a 50-day moving average of $73.51 and a 200-day moving average of $63.34. The stock has a market cap of $4.72 billion, a PE ratio of -28.35 and a beta of 1.76. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. During the same quarter in the prior year, the business posted ($1.41) EPS. The business's quarterly revenue was up 3253.3% compared to the same quarter last year. As a group, analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.
Hedge Funds Weigh In On CRISPR Therapeutics
Hedge funds have recently bought and sold shares of the business. Blue Trust Inc. bought a new position in CRISPR Therapeutics during the fourth quarter worth about $32,000. Bourgeon Capital Management LLC increased its position in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock worth $34,000 after acquiring an additional 500 shares during the period. Main Street Group LTD bought a new position in CRISPR Therapeutics during the fourth quarter worth about $34,000. CWM LLC increased its position in CRISPR Therapeutics by 80.7% during the third quarter. CWM LLC now owns 582 shares of the company's stock worth $26,000 after acquiring an additional 260 shares during the period. Finally, NBC Securities Inc. increased its position in CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company's stock worth $41,000 after acquiring an additional 438 shares during the period. 69.20% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
CRSP has been the subject of a number of analyst reports. Chardan Capital raised their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. Royal Bank of Canada raised their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a "sector perform" rating in a research report on Thursday, February 22nd. Wells Fargo & Company increased their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an "equal weight" rating in a research note on Thursday, February 22nd. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. Finally, Morgan Stanley increased their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a research note on Monday, February 26th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $74.93.
Read Our Latest Stock Analysis on CRSP
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
